Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium Journal Article


Authors: Bayraktar, U. D.; Ramos, J. C.; Petrich, A.; Gupta, N.; Lensing, S.; Moore, P. C.; Reid, E. G.; Aboulafia, D. M.; Ratner, L.; Mitsuyasu, R.; Cooley, T.; Henry, D. H.; Barr, P.; Noy, A.
Article Title: Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium
Abstract: No comparative studies exist for relapsed/refractory (rel/rfr) acquired immune deficiency syndrome (AIDS)-related lymphoma (ARL). To determine practices over the last decade and to assess the outcomes of salvage chemotherapy with curative intent and autologous stem cell transplant (ASCT), we retrospectively evaluated treatment outcomes in patients with rel/rfr ARL who were treated in 13 national AIDS Malignancy Consortium (AMC) sites between 1999 and 2008 (n 88). The most commonly used second-line therapies were ICE (ifosfamide/carboplatin/ etoposide, n 34), dose adjusted EPOCH (etoposide/prednisone/vincristine/ cyclophosphamide/doxorubicin, n 17) and ESHAP (etoposide/methylprednisolone/ cytarabine/cisplatin, n 11). The odds of achieving a response were lower for those with non-Hodgkin lymphoma (NHL) than for those with HL and for those with primary refractory disease than for those with relapse. Overall survival (OS) was significantly longer for those with relapsed disease compared to those with refractory disease and for those with non-Burkitt NHL compared to those with Burkitt. OS was longer in patients who underwent ASCT compared to those who did not (1-year OS: 63.2% vs. 37.2%). However, among 32 patients (36%) who achieved a complete or partial reponse (CR/PR) after second-line therapy, 1-year OS was not different between the two groups (87.5% for ASCT vs. 81.8% for non-ASCT). Long-term survival in some patients with rel/rfr ARL may be possible without transplant, although transplant remains the standard of care for chemotherapy sensitive disease. © 2012 Informa UK, Ltd.
Keywords: salvage therapy; stem cell transplant; lymphoma; acquired immune deficiency syndrome
Journal Title: Leukemia and Lymphoma
Volume: 53
Issue: 12
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2012-12-01
Start Page: 2383
End Page: 2389
Language: English
DOI: 10.3109/10428194.2012.697559
PROVIDER: scopus
PMCID: PMC3458169
PUBMED: 22642936
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 3 December 2012" - "CODEN: LELYE" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Ariela Noy
    334 Noy
  2. Neel Kamal Gupta
    5 Gupta